PRIMARY CNS LYMPHOMA TREATED WITH HIGH-DOSE METHOTREXATE AND RITUXIMAB - SINGLE INSTITUTION EXPERIENCE

被引：0
|
作者：
Mrugala, M. M. [1 ]
Crew, L. K. [1 ]
机构：
[1] Univ Washington, Seattle, WA 98195 USA
来源：
NEURO-ONCOLOGY | 2012年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：84 / 84
页数：1
相关论文
共 50 条
  • [21] Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphoma
    Green, Myke R.
    Chowdhary, Sajeel
    Lombardi, Kristina M.
    Chalmers, Lisa M.
    Chamberlain, Marc
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2006, 6 (05) : 635 - 652
  • [22] Treatment of Primary CNS Lymphoma With High-Dose Methotrexate in Immunocompetent Pediatric Patients
    Shah, Amish C.
    Kelly, David R.
    Nabors, L. Burt
    Oakes, W. Jerry
    Hilliard, Lee M.
    Reddy, Alyssa T.
    PEDIATRIC BLOOD & CANCER, 2010, 55 (06) : 1227 - 1230
  • [23] Prognostic impact of completion of initial high-dose methotrexate therapy on primary central nervous system lymphoma: a single institution experience
    Keishi Makino
    Hideo Nakamura
    Taku-ichiro Hide
    Jun-ichiro Kuroda
    Shigetoshi Yano
    Jun-ichi Kuratsu
    International Journal of Clinical Oncology, 2015, 20 : 29 - 34
  • [24] Prognostic impact of completion of initial high-dose methotrexate therapy on primary central nervous system lymphoma: a single institution experience
    Makino, Keishi
    Nakamura, Hideo
    Hide, Taku-ichiro
    Kuroda, Jun-ichiro
    Yano, Shigetoshi
    Kuratsu, Jun-ichi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2015, 20 (01) : 29 - 34
  • [25] High-dose methotrexate and rituximab induction regimen in immunocompetent patients with primary CNS lymphoma: a retrospective single-center study of survival predictors
    Andrew B. DeAtkine
    Moaaz Abdelrashid
    Zach Tucker
    Amitkumar Mehta
    James M. Markert
    Jinsuh Kim
    John B. Fiveash
    Robert A. Oster
    Mina Lobbous
    L. Burt Nabors
    Journal of Neuro-Oncology, 2022, 158 : 33 - 40
  • [26] High-dose methotrexate and rituximab induction regimen in immunocompetent patients with primary CNS lymphoma: a retrospective single-center study of survival predictors
    DeAtkine, Andrew B.
    Abdelrashid, Moaaz
    Tucker, Zach
    Mehta, Amitkumar
    Markert, James M.
    Kim, Jinsuh
    Fiveash, John B.
    Oster, Robert A.
    Lobbous, Mina
    Nabors, L. Burt
    JOURNAL OF NEURO-ONCOLOGY, 2022, 158 (01) : 33 - 40
  • [27] High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial
    Ferreri, Andres J. M.
    Reni, Michele
    Foppoli, Marco
    Martelli, Maurizio
    Pangalis, Gerasimus A.
    Frezzato, Maurizio
    Cabras, Maria Giuseppina
    Fabbri, Alberto
    Corazzelli, Gaetano
    Ilariucci, Fiorella
    Rossi, Giuseppe
    Soffietti, Riccardo
    Stelitano, Caterina
    Vallisa, Daniele
    Zaja, Francesco
    Zoppegno, Lucia
    Aondio, Gian Marco
    Avvisati, Giuseppe
    Balzarotti, Monica
    Brandes, Alba A.
    Fajardo, Jose
    Gomez, Henry
    Guarini, Attilio
    Pinotti, Graziella
    Rigacci, Luigi
    Uhlmann, Catrina
    Picozzi, Piero
    Vezzulli, Paolo
    Ponzoni, Maurilio
    Zucca, Emanuele
    Caligaris-Cappio, Federico
    Cavalli, Franco
    LANCET, 2009, 374 (9700): : 1512 - 1520
  • [28] Alternative Consolidation Strategy after High Dose Methotrexate, Rituximab and Temozolamide in Primary CNS Lymphoma - the Henry Ford Experience
    Philip, Joyce
    Sharma, Shivani
    Donthireddy, Vijayalakshmi
    BLOOD, 2020, 136
  • [29] HIGH-DOSE METHOTREXATE BASED IMMUNOCHEMOTHERAPY WITH MAINTENANCE CHEMOTHERAPY WITH HIGH-DOSE METHOTREXATE AND DEFERRED RADIOTHERAPY FOR ELDERLY PRIMARY CNS LYMPHOMA PATIENTS
    Mishima, K.
    Miyake, Y.
    Kobayashi, Y.
    Suzuki, T.
    Adachi, J.
    Fujimaki, T.
    Nishikawa, R.
    NEURO-ONCOLOGY, 2017, 19 : 108 - 109
  • [30] High-dose therapy for primary CNS lymphoma
    Hohaus, Stefan
    Lancet Haematology, 2016, 3 (08): : E359 - E360
12345